subscribeSubscribe
EMA validates Pierre Fabre`s MAA for BRAFTOVI

EMA validates Pierre Fabre`s MAA for BRAFTOVI
PR NEWSWIRE
02 Nov 2023
Share Share
US clears Pfizer`s Braftovi, Mektovi combo for use in lung cancer

US clears Pfizer`s Braftovi, Mektovi combo for use in lung cancer
BUSINESSWIRE
13 Oct 2023
Share Share
Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC

Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC
Kyle Doherty ONCLIVE
31 Aug 2023
Share Share
Enforcement Report - Week of April 19, 2023

Enforcement Report - Week of April 19, 2023
FDA
19 Apr 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Mektovi (Binimetinib)

FDA Confirms Paragraph IV Patent Litigation for Mektovi (Binimetinib)
FDA
24 Aug 2022
Share Share
Amber Specialty Added to Pfizer’s Limited Distribution Network

Amber Specialty Added to Pfizer’s Limited Distribution Network
BUSINESSWIRE
03 Aug 2022
Share Share
OnKure Begins Dosing in PIb/II Nautilus Trial of OKI-179 + Binimetinib

OnKure Begins Dosing in PIb/II Nautilus Trial of OKI-179 + Binimetinib
GLOBENEWSWIRE
02 Jun 2022
Share Share
EORTC and Pierre Fabre launch phase 3 trial for melanoma

EORTC and Pierre Fabre launch phase 3 trial for melanoma
Fleur Jeffries PMLIVE
27 May 2022
Share Share
Pierre Fabre & EORTC open a large Phase III clinical study the adjuvant setting

Pierre Fabre & EORTC open a large Phase III clinical study the adjuvant setting
PRESS RELEASE
24 May 2022
Share Share
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib

IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib
PRNEWSWIRE
23 Mar 2021
Share Share